Cancer Research Institute Media Room




Health Media Network and Cancer Research Institute Team Up to Drive Education and Awareness about Cancer Immunotherapy and Clinical Trials

Health Media Network (HMN), a leading and trusted Digital Point of Care company, has teamed up with the Cancer Research Institute (CRI), a nonprofit organization dedicated to saving more lives by advancing scientific efforts to develop new and effective immunotherapies for all forms of cancer, to distribute CRI’s cancer immunotherapy and clinical trials education and awareness programming at the Point of Care.

Over the past six years, the FDA has approved immunotherapies as treatments for nearly 20 cancers including cancers with a specific genetic mutation. The field is advancing rapidly, and as immunotherapy becomes more widely available as a treatment option, the goal is to provide patients and their caregivers with information to help them make the most informed decisions with their oncologists in the most trusted Point of Care environment through Health Media Network.

“We are proud to partner with the Cancer Research Institute to increase awareness of immunotherapy and clinical trials,” said Christopher J. Culver, CEO of Health Media Network. “Leveraging Health Media Network’s Point of Care environment, where and when patients are actively engaged in HCP discussions and educating themselves on the various pathways available is an important step in making informed healthcare decisions.”

“Through our partnership with Health Media Network, the Cancer Research Institute is able to significantly expand its reach to deliver our expert-vetted information about immunotherapy to patients and caregivers who may be learning for the first time about this new approach to treating cancer and who would benefit from engaging their professional health care teams in conversation about their immunotherapy options,” said Jill O’Donnell-Tormey, PhD, CEO and director of scientific affairs at the Cancer Research Institute.

About Health Media Network
Health Media Network (HMN) is a leading and trusted Digital Point of Care media company. HMN provides targeted health education in Physician Waiting Rooms and Hospital Systems to advance consumer health literacy and facilitate better doctor/patient conversations.

With 12,000 media touchpoints, reaching 55,000+ health care professionals, and the most robust mobile health activation in the Point of Care market, HMN impacts an estimated 325MM+ patient and caregiver impressions annually. HMN provides physicians and brands with the ability to segment with customized messaging—with the overall goal of improving health population outcomes. For more information, visit

About Cancer Research Institute
The Cancer Research Institute (CRI), established in 1953, is the world’s leading nonprofit organization dedicated exclusively to saving more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. Guided by a world-renowned Scientific Advisory Council that includes four Nobel laureates and 24 members of the National Academy of Sciences, CRI has invested $400 million in support of research conducted by immunologists and tumor immunologists at the world’s leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to

Useful links:
Health Media Network:
Cancer Research Institute:

Follow us on social media: 

Health Media Network
Twitter: @HMN_ads
Facebook: @HealthMediaNetwork

Cancer Research Institute
Instagram: @CancerResearchInstitute
Facebook: @CancerResearchInstituteInc
Twitter: @CancerResearch

Media Contacts:

For Health Media Network:
Alicesa Vongluekiat – Senior Vice President, Marketing
[email protected]

For Cancer Research Institute:
Brian Brewer – Director of Marketing and Communications
212-688-7515 ext. 242
[email protected]

Read more:

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.